Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1985 Sep;76(3):1243-51.
doi: 10.1172/JCI112080.

Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma

Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma

F Caligaris-Cappio et al. J Clin Invest. 1985 Sep.

Abstract

Precursors of plasma cells were studied in the bone marrow of 28 patients with multiple myeloma, plasma cell leukemia, and benign monoclonal gammopathy. Pre-B and B cell populations were analyzed with anti-B monoclonal antibodies corresponding to the clusters standardized at the Leucocyte Typing Workshops in Paris and Boston (CD9, CD10, CD19-22, CD24). In advanced forms of plasma cell malignancies, such as cases of multiple myeloma in stages II and III and of plasma cell leukemia, some cells of lymphoid morphology expressed common acute lymphoblastic leukemia antigen (CALLA, CD10) and HLA-DR, but contained no detectable terminal deoxynucleotidyl transferase enzyme. These CALLA+ cells were absent in benign monoclonal gammopathies. In multiple myeloma, the CALLA+ cells were negative for surface and cytoplasmic immunoglobulins (Ig), and, unlike CALLA+, terminal deoxynucleotidyl transferase (TdT+) pre-B cells in the normal bone marrow also failed to react with antibodies to B cell-associated antigens such as CD9, CD19, CD22, and CD24. The CALLA+, Ig- cells could be regarded as preplasmacytic since, after having been separated and stimulated with the phorbol ester 12-0-tetradecanoyl-phorbol-13 acetate in vitro, they transformed into plasma cells and synthesized the same heavy and light chains as myeloma cells.

PubMed Disclaimer

References

    1. Lancet. 1966 Jan 15;1(7429):119-21 - PubMed
    1. Hum Immunol. 1984 Jan;9(1):9-20 - PubMed
    1. J Clin Pathol. 1973 Sep;26(9):649-59 - PubMed
    1. Haematologica. 1974 Mar;59(1):10-24 - PubMed
    1. Arch Intern Med. 1975 Jan;135(1):125-30 - PubMed

Publication types

MeSH terms